Artificial intelligence is beginning to produce measurable efficiency gains in cancer clinical trials, according to a new analysis from the Tufts Center for the Study of Drug Development. AI-powered tools can assist with patient recruitment and enrollment, clinical monitoring, data processing, and interpretation of results—areas that often consume substantial amounts of time and money. The findings suggest that AI could move beyond experimental use and become a meaningful part of clinical-trial operations.
The Tufts analysis found that an AI agent could accelerate cancer-drug development by about 10 weeks and reduce direct operating costs by as much as $5.6 million in late-stage trials. The researchers modeled the use of Medable's clinical-monitoring agent in a Phase 2 and Phase 3 oncology development program. The potential financial benefit becomes much larger when a drug has multiple possible cancer indications: a treatment with 50 active uses could potentially generate net benefits of up to $565 million, according to the analysis.
AI can create these efficiencies by reducing some of the administrative and monitoring burden associated with trials. The technology can help accelerate enrollment, reduce the number of on-site visits, process clinical data faster, and identify information about a drug's safety and effectiveness earlier. AI agents could eventually handle much of the repetitive record-keeping required during regulatory submissions, allowing researchers to spend more time on strategic scientific and clinical decisions. Medable officials estimate that such agents could become standard components of some clinical trials within three to five years.
However, AI cannot solve every problem involved in running a clinical trial. Some of the hardest challenges involve finding appropriate patients, obtaining informed consent, and manufacturing and distributing the drug, rather than processing information. Human experts will also need to verify AI-generated work, which could reduce some of the claimed time savings. The broader significance is therefore not that AI will replace clinical researchers, but that it could remove substantial operational friction from trials—potentially making drug development faster, less expensive, and capable of supporting more studies with the same resources.
